Microsoft, weight loss drug sales, and GSK profits surge


In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Ireland secure bonus-point win over Wales
Tesla Cybertruck drives through water in first real-world Wade Mode test
Young girl dies after being buried by sand while digging hole on beach
Italy miss chance to beat France in dramatic draw
Mercedes-Benz drastically backtracks EV plans, will build gas cars well into 2030s